Boosting ADR Reporting: Assessing Knowledge, Attitude, and Practices Among UAE Hospital Pharmacists

By HEOR Staff Writer

August 2, 2023

A recent study aimed to evaluate the knowledge, attitudes, and practices (KAP) of hospital pharmacists in the UAE regarding Adverse Drug Reaction (ADR) reporting and the barriers to implementing a Pharmacovigilance (PV) system.

Although pharmacists generally display a positive attitude towards ADR reporting, the level of reporting remains low, which may be due to a lack of knowledge about PV and ADRs, including what, where, and when to report.

Interestingly, findings showed that gender does not affect awareness of PV and ADR reporting, but educational level and years of experience do. Hospital pharmacists with less than five years of experience lack the expertise of those with 10-14 years of experience in PV and ADR reporting.

Despite observing ADRs, only half of the participants reported them. This underreporting could be due to poor time management, lack of awareness of the reporting process, difficulties in accessing ADR reports, and poor patient-pharmacist communication.

They also found that the role and years of experience influence the likelihood of ADR reporting. Clinical pharmacists and inpatient pharmacists are more likely to engage in PV due to their direct patient care experience.

In terms of barriers, over half of the pharmacists cited a lack of knowledge about the reporting process. Fear of repercussions from management and legal culpability were also mentioned.

To improve ADR reporting, they recommend incentives for reporting, conducting workshops and ongoing education, providing legal protection, and ensuring easy online access to ADR forms.

Reference url

Recent Posts

EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...
vulnerable elderly care
Mapping Vulnerable Elderly Care in the Netherlands

By HEOR Staff Writer

June 22, 2026

As the Netherlands confronts rapid societal aging, effective vulnerable elderly care has become an urgent policy priority. One in four community-dwelling adults aged 65 and older lives with vulnerable health, according to Longitudinal Aging Study Amsterdam (LASA) data, marking a critical target g...
CAPVAXIVE Pediatric Vaccine Approval
Advancing CAPVAXIVE Pediatric Vaccine Approval for High-Risk Youth

By João L. Carapinha

June 19, 2026

The CAPVAXIVE Pediatric Vaccine Approval expands options for children and adolescents aged 2 through 17 who have completed their primary pediatric pneumococcal series yet face elevated risk due to chronic conditions such as diabetes, heart disease, kidney disease, liver disease, or lung disease. ...